Actinium Pharmaceuticals, Inc. (ATNM)
1.57
+0.19
(+13.77%)
USD |
NYAM |
Oct 22, 15:29
Actinium Pharmaceuticals Profit Margin (Quarterly) : 79.72% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 79.72% |
| March 31, 2026 | |
| December 31, 2025 | |
| September 30, 2025 | -5.70K% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | -11.51K% |
| Date | Value |
|---|---|
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | -21.05K% |
| June 30, 2022 | -17.26K% |
| March 31, 2022 | -545.6% |
| December 31, 2021 | -34.83K% |
| September 30, 2021 | -2.76K% |
| June 30, 2021 | -1.89K% |
| March 31, 2021 | -855.3% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 77.20% |
| Return on Assets | 22.00% |
| Return on Invested Capital | 70.48% |
| Gross Profit Margin (Quarterly) | 98.77% |
| Operating Margin (Quarterly) | 78.76% |
| Return on Net Operating Assets | 548.7% |